Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc. (RPHM) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
rphm · stock forecast · 7 analysts (3M) · FMP · updated Jan 8, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $18.20
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $19.11 | ↑ 5.00% |
1-day model range: $18.96–$19.26. Peak: $19.26 (+5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RPHM · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-05-14 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2023-12-15 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2023-12-15 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2023-12-15 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-11-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-10-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-10-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-09-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-09-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-05-18 | Piper Sandler | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Reneo Pharmaceuticals, Inc. (RPHM) stock. Of the recent 19 rating actions, 0 were upgrades and 3 were downgrades. 7 analysts currently cover RPHM.
Analyst Recommendation Trends
RPHM analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$0M
EPS This Year
$-2.37
EPS Next Year
$-0.65
↓ 72.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast RPHM EPS of $-2.37 for the current fiscal year, based on estimates from 5 analysts. The RPHM revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RPHM stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RPHM price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The RPHM short-term stock prediction for tomorrow is $19.11 (+5.00%).
Reneo Pharmaceuticals, Inc. trades on NASDAQ under the ticker RPHM. The RPHM stock outlook for 2027 is broadly positive, supported by a Buy consensus among 57% of covering analysts.
Frequently asked questions
RPHM forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month RPHM price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $18.20.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.